Iron chelation therapy for myelodysplastic syndrome: if and when.
Tefferi
Ayalew
A
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu
D001565:Benzoates / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D003362:Cost-Benefit Analysis; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox